S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Forecast, Price & News

$5.10
-0.21 (-3.95%)
(As of 09/29/2023 ET)
Compare
Today's Range
$4.95
$5.29
50-Day Range
$5.10
$8.90
52-Week Range
$4.95
$60.00
Volume
5,650 shs
Average Volume
17,280 shs
Market Capitalization
$8.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$210.00

Finch Therapeutics Group MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
4,017.6% Upside
$210.00 Price Target
Short Interest
Bearish
5.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Finch Therapeutics Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($30.98) to ($20.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars


FNCH stock logo

About Finch Therapeutics Group (NASDAQ:FNCH) Stock

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

FNCH Price History

FNCH Stock News Headlines

Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.6%
New Breakthrough "Living Software" Has Been…
New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." Early investors can reap 5,633% gains on the small company revolutionizing warfare >>>
8-K: Finch Therapeutics Group, Inc.
Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
FINCH THERAPEUTICS GROUP INC
Finch Therapeutics Group (FNCH) Gets a Buy from H.C. Wainwright
FNCH Finch Therapeutics Group, Inc.
Finch Therapeutics To Reduce Workforce - Quick Facts
See More Headlines
Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

FNCH Company Calendar

Last Earnings
8/10/2023
Today
9/29/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FNCH
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$210.00
High Stock Price Forecast
$210.00
Low Stock Price Forecast
$210.00
Forecasted Upside/Downside
+4,017.6%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-114,650,000.00
Net Margins
-25,084.36%
Pretax Margin
-56,019.37%

Debt

Sales & Book Value

Annual Sales
$860,000.00
Book Value
$60.01 per share

Miscellaneous

Free Float
884,000
Market Cap
$8.16 million
Optionable
Not Optionable
Beta
0.17
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Matthew P. Blischak J.D.
    Chief Exec. Officer
  • Mr. Lance Thibault CPA (Age 57)
    CPA, Chief Financial Officer
  • Mr. James S. Sigler MBA (Age 62)
    Exec. VP of CMC













FNCH Stock - Frequently Asked Questions

What is Finch Therapeutics Group's stock price forecast for 2023?

0 brokers have issued 12-month target prices for Finch Therapeutics Group's stock. Their FNCH share price forecasts range from $210.00 to $210.00. On average, they expect the company's share price to reach $210.00 in the next twelve months. This suggests a possible upside of 4,017.6% from the stock's current price.
View analysts price targets for FNCH
or view top-rated stocks among Wall Street analysts.

How have FNCH shares performed in 2023?

Finch Therapeutics Group's stock was trading at $14.40 on January 1st, 2023. Since then, FNCH stock has decreased by 64.6% and is now trading at $5.10.
View the best growth stocks for 2023 here
.

Are investors shorting Finch Therapeutics Group?

Finch Therapeutics Group saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 28,500 shares, an increase of 27.2% from the August 31st total of 22,400 shares. Based on an average daily trading volume, of 10,500 shares, the short-interest ratio is presently 2.7 days. Currently, 5.1% of the company's stock are sold short.
View Finch Therapeutics Group's Short Interest
.

When is Finch Therapeutics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our FNCH earnings forecast
.

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its earnings results on Thursday, August, 10th. The company reported ($4.33) earnings per share for the quarter, topping the consensus estimate of ($4.51) by $0.18. Finch Therapeutics Group had a negative trailing twelve-month return on equity of 115.37% and a negative net margin of 25,084.36%.

When did Finch Therapeutics Group's stock split?

Finch Therapeutics Group's stock reverse split on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Finch Therapeutics Group IPO?

(FNCH) raised $101 million in an IPO on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

What is Finch Therapeutics Group's stock symbol?

Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH."

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Finch Therapeutics Group's stock price today?

One share of FNCH stock can currently be purchased for approximately $5.10.

How much money does Finch Therapeutics Group make?

Finch Therapeutics Group (NASDAQ:FNCH) has a market capitalization of $8.16 million and generates $860,000.00 in revenue each year. The company earns $-114,650,000.00 in net income (profit) each year or ($86.6130) on an earnings per share basis.

How can I contact Finch Therapeutics Group?

The official website for the company is www.finchtherapeutics.com. The company can be reached via phone at 617-229-6499 or via email at ir@finchtherapeutics.com.

This page (NASDAQ:FNCH) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -